Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ONCY 
Oncolytics Biotech Inc (ONCY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ONCY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.63
1 Year Target Price $4.63
| 1 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.52% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 105.30M USD | Price to earnings Ratio - | 1Y Target Price 4.63 |
Price to earnings Ratio - | 1Y Target Price 4.63 | ||
Volume (30-day avg) 6 | Beta 1.09 | 52 Weeks Range 0.33 - 1.53 | Updated Date 08/30/2025 |
52 Weeks Range 0.33 - 1.53 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Earnings Date
Report Date 2025-08-08 | When - | Estimate -0.0885 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -74.56% | Return on Equity (TTM) -249.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 95305764 | Price to Sales(TTM) - |
Enterprise Value 95305764 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.79 | Shares Outstanding 101246000 | Shares Floating 98776415 |
Shares Outstanding 101246000 | Shares Floating 98776415 | ||
Percent Insiders 3.61 | Percent Institutions 1.68 |
Upturn AI SWOT
Oncolytics Biotech Inc
Company Overview
History and Background
Oncolytics Biotech Inc. was founded in 1998. It's a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Significant milestones include advancing Reolysin through clinical trials and establishing partnerships for development and commercialization.
Core Business Areas
- Reolysin Development: Development of Reolysin, an oncolytic virus, for the treatment of various cancers, including breast cancer, pancreatic cancer and head and neck cancer. The company works towards clinical trials and potential market launch.
Leadership and Structure
The leadership team consists of individuals with experience in the biotechnology and pharmaceutical industries. The company is structured around research and development, clinical trials, and corporate management.
Top Products and Market Share
Key Offerings
- Reolysin: Reolysin is Oncolytics Biotech Inc.'s primary product, an oncolytic virus being investigated as a cancer therapeutic in clinical trials. Currently, it does not have market share. Competitors include other oncolytic virus developers like Amgen (IMLYGIC), BioVaxys Technology Corp (BIOV.CN), and Replimune (REPL).
Market Dynamics
Industry Overview
The oncolytic virus therapy market is growing, driven by the potential of these viruses to selectively target and destroy cancer cells. There's increasing interest and investment in this field, with several companies developing novel oncolytic virus therapies.
Positioning
Oncolytics Biotech Inc. is positioned as a developer of Reolysin, aiming to demonstrate its efficacy in various cancer types. The company's competitive advantage lies in the potential of Reolysin and it targets specific cancer indications.
Total Addressable Market (TAM)
The oncolytic virus therapy market is projected to reach billions of dollars. Oncolytics' TAM is tied to the specific cancer indications Reolysin targets and how they advance in clinical trials. The TAM for oncolytic virus therapy is projected to be between $700 million and $1 billion by 2028.
Upturn SWOT Analysis
Strengths
- Proprietary Reolysin technology
- Clinical trial progress
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on Reolysin's success
- Lack of commercialized product
Opportunities
- Positive clinical trial results
- Partnerships with pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from other therapies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- AMGN
- REPL
- VIRI
Competitive Landscape
Oncolytics faces competition from larger pharmaceutical companies with more resources and marketed products. However, Oncolytics' specific focus on Reolysin in targeting specific cancer indications provides a unique competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely driven by advancements in the clinical trials for Reolysin
Future Projections: Future growth hinges on successful clinical trial outcomes, regulatory approvals, and partnerships.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials and seeking partnerships for further development of Reolysin.
Summary
Oncolytics Biotech is in early stages with strong potential but requires more time for development. Its main strength lies in Reolysin, but its financial situation and the success of clinical trials are crucial to watch. Positive clinical trial results and partnerships could drive significant growth, while regulatory hurdles and competition pose ongoing threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate. The AI rating is generated based on currently available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oncolytics Biotech Inc
Exchange NASDAQ | Headquaters Calgary, AB, Canada | ||
IPO Launch date 1999-11-08 | CEO & Director Mr. Jared Kelly J.D., L.L.M. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://oncolyticsbiotech.com |
Full time employees 28 | Website https://oncolyticsbiotech.com | ||
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.